image

Investors

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Media Contact:
Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
Lwolffe@wheelhouselsa.com

Date Title and Summary Additional Format
March 6, 2024 Nurix Therapeutics to Participate in Upcoming Investor Conferences
SAN FRANCISCO, March 06, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today announced that Hans van Houte, Nurix’s chief
March 5, 2024 Nurix Therapeutics Announces Presentations at the American Association for Cancer Research (AACR) 2024 Annual Meeting
Nurix CSO Gwenn M. Hansen, Ph.D., invited as a featured presenter in two separate sessions focused on next-gen degraders and delivering degraders to the site of action SAN FRANCISCO, March 05, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical
February 15, 2024 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides a Corporate Update
NX-5948 received Fast Track designation from the FDA NX-5948 showed positive results in Phase 1 clinical trial establishing a robust foundation for advancement in CLL Licensed to Gilead a new development candidate, NX-0479/GS-6791, a targeted protein degrader of IRAK-4 for rheumatoid arthritis
February 1, 2024 Nurix Therapeutics Announces Publication in the Journal Science Identifying a New Class of BTK Mutations That Are Susceptible to NX-2127, a Novel BTK and IKZF1/3 Degrader
Data reveal oncogenic scaffold function of BTK mutations that lack kinase activity and show these mutations remain susceptible to degradation by NX-2127 NX-2127 degrades BTK in patients regardless of mutational status and shows proof-of-concept therapeutic benefit in chronic lymphocytic leukemia
January 16, 2024 Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory CLL and SLL
Fast track designation follows positive Phase 1 data presented at the American Society of Hematology that supports strategy to broadly develop NX-5948 in CLL and other non-Hodgkin lymphoma indications SAN FRANCISCO, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc.
January 8, 2024 Nurix Therapeutics Outlines 2024 Strategic Priorities with Advancement of Targeted Protein Modulation Pipeline in Cancer and Autoimmune Diseases
Positive Phase 1 data presented at American Society of Hematology supports prioritizing the acceleration of enrollment of NX-5948 in leukemia and lymphoma Strategic collaborations in small molecule, targeted protein degradation with Gilead and Sanofi, and degrader antibody conjugates with Pfizer
January 2, 2024 Nurix Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
SAN FRANCISCO, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T.
Displaying 21 - 27 of 27